Abstract:The supply and control of iron is essential for all cells and vital for many physiological processes. All functions and activities of iron are expressed in conjunction with iron-binding molecules. For example, natural chelators such as transferrin and chelator–iron complexes such as haem play major roles in iron metabolism and human physiology. Similarly, the mainstay treatments of the most common diseases of iron metabolism, namely iron deficiency anaemia and iron overload, involve many iron–chelator complexes and the iron-chelating drugs deferiprone (L1), deferoxamine (DF) and deferasirox. Endogenous chelators such as citric acid and glutathione and exogenous chelators such as ascorbic acid also play important roles in iron metabolism and iron homeostasis. Recent advances in the treatment of iron deficiency anaemia with effective iron complexes such as the ferric iron tri-maltol complex (feraccru or accrufer) and the effective treatment of transfusional iron overload using L1 and L1/DF combinations have decreased associated mortality and morbidity and also improved the quality of life of millions of patients. Many other chelating drugs such as ciclopirox, dexrazoxane and EDTA are used daily by millions of patients in other diseases. Similarly, many other drugs or their metabolites with iron-chelation capacity such as hydroxyurea, tetracyclines, anthracyclines and aspirin, as well as dietary molecules such as gallic acid, caffeic acid, quercetin, ellagic acid, maltol and many other phytochelators, are known to interact with iron and affect iron metabolism and related diseases. Different interactions are also observed in the presence of essential, xenobiotic, diagnostic and theranostic metal ions competing with iron. Clinical trials using L1 in Parkinson's, Alzheimer's and other neurodegenerative diseases, as well as HIV and other infections, cancer, diabetic nephropathy and anaemia of inflammation, highlight the importance of chelation therapy in many other clinical conditions. The proposed use of iron chelators for modulating ferroptosis signifies a new era in the design of new therapeutic chelation strategies in many other diseases. The introduction of artificial intelligence guidance for optimal chelation therapeutic outcomes in personalised medicine is expected to increase further the impact of chelation in medicine, as well as the survival and quality of life of millions of patients with iron metabolic disorders and also other diseases.

Physiological iron chelators pyrophosphate and citrate have different effects on the proportions of monoferric transferrin metalloforms

A new role for the transferrin receptor in the release of iron from transferrin

Pharmacokinetics of Ferric Pyrophosphate Citrate, a Novel Iron Salt, Administered Intravenously to Healthy Volunteers

Synthesis, Physicochemical Properties, and Evaluation of<i>N</i>-Substituted-2-alkyl-3-hydroxy-4(1<i>H</i>)-pyridinones<sup>†</sup>

Increased Prospects for the Effective Treatment of Iron Overload and Iron Deficiency

The iron(III) coordinating properties of citrate and α-hydroxycarboxylate containing siderophores

Protein sialylation affects the pH-dependent binding of ferric ion to human serum transferrin

Ferrous iron content of intravenous iron formulations

Monoclonal Antibodies to Transferrin Receptors

Iron chelating agents for the treatment of iron overload

Effect of oxidation state and chelating agent on iron bio-accessibility from different commercial iron-supplements

Synthetic and natural iron chelators: therapeutic potential and clinical use

[Effects of Iron Supplementation on Human Serum Level of Transferrin Receptor].

Regulation mechanisms of ferric ions release from iron-loaded transferrin protein caused by nano-sized polystyrene plastics-induced conformational and structural changes

Relative Mobility of Human Transferrin Domains Accounts for Its Efficient Recognition and Recycling

Oral Non-absorbable Polymer-Deferoxamine Conjugates for Reducing Dietary Iron Absorption

Comparing soluble ferric pyrophosphate to common iron salts and chelates as sources of bioavailable iron in a Caco-2 cell culture model

Iron and Chelation in Biochemistry and Medicine: New Approaches to Controlling Iron Metabolism and Treating Related Diseases

Route of intestinal absorption and tissue distribution of iron contained in the novel phosphate binder ferric citrate

Structure, Function and Clinical Significance of Transferrin Receptors

New Deferric Amine Compounds Efficiently Chelate Excess Iron to Treat Iron Overload Disorders and to Prevent Ferroptosis